Italy Patient Support Programs Market Report 2022 to 2030

Italy Patient Support Programs (PSP) Market Analysis

$ 3999$ 2999

Italy's Patient Support Programs (PSP) market is expected to grow from $xx Bn in 2022 to $xx Bn in 2030 with a CAGR of 9.4% for the year 2022-30. Simpler and affordable patient-centric services due to recent developments like telemedicine and support from the Italian government for patient empowerment and self-management are major market drivers for the growth of the Italy Patient Support Programs (PSP) market. The market is segmented by functionality outlook, therapeutic outlook, application outlook, and the end user. Some of the top PSP operators in the Italy Patient Support Programs (PSP) market are Domedica, Sarpharma, and Healthcare Network Partners

ID: IN10ITHS014 CATEGORY: Healthcare Services GEOGRAPHY: Italy AUTHOR: Parul Choudhary

Buy Now

Italy Patient Support Programs (PSP) Market Executive Analysis

Italy's Patient Support Programs (PSP) market size is at around $xx Bn in 2022 and is projected to reach $xx Bn in 2030, exhibiting a CAGR of 9.4% during the forecast period. According to the World Health Organization (WHO), Italy is one of the top 10 countries for providing high-quality healthcare. Italian healthcare is ranked as the second-best in the world by the WHO. At 79.4 years for males and 84.8 years for women, life expectancy is comparatively high.

In Italy, the National Health System (NHS) costs that the State contributes to are determined annually by the Finance Act at a general level of resources. The National Health Fund (NHF), which will increase from $130.56 Bn to $132.70 Bn in 2022, to $134.84 Bn in 2023, and to $136.98 Bn in 2024, has received an additional $2.14 Bn over the course of the next three years according to the 2022 Finance Act. In addition to those envisioned under the National Recovery and Resilience Plan (PNRR), new funding has been committed to ensuring the execution of organizational, quantitative, qualitative, and technological standards.

Patient Support Programs (PSPs) are an umbrella term for activities sponsored by pharmaceutical corporations to promote prescription drug availability, consumption, and adherence. PSPs can be divided into three primary categories: financial help, clinical support, and support for adherence. A single PSP may include elements from each of these category types. The Novartis-funded PSP PSOLife CARE, developed and implemented by IQVIA, was intended to assist Italian psoriasis patients receiving Secukinumab medication. This PSP came at no cost to the patients or the Italian National Health Services.

The Italian Pharmaceutical Industry Association (Farmindustria) endorsed new recommendations for patient support programs on January 19, 2022. According to the new standards, patient support programs are actions taken by pharmaceutical companies with the intention of providing additional services that directly benefit patients. These services are not meant to take the place of those offered by hospitals and other healthcare facilities. Regarding the handling of patient personal data, the new regulations provide that pharmaceutical corporations must only access aggregated data for statistical analysis of the use of the services rather than directly processing the data of patients participating in patient support programs.

italy patient support program market analysis

Market Dynamics

Market Growth Drivers

Delivering patient support services has become simpler and more affordable owing to developments in digital health technology like telemedicine and remote patient monitoring. Consequently, Italy's PSP market now has more opportunities. The Italian government has promoted the creation and implementation of patient support programs by enacting a number of regulations and initiatives. To assist patient empowerment and self-management, the Ministry of Health, for example, has started a national program that involves the development of patient support programs.

Market Restraints

PSPs' advantages and their proper use may not be completely grasped by patients and healthcare professionals. The adoption of PSPs may be limited by this lack of knowledge and guidance, and patients may not benefit fully from these programs thereby limiting the Italy PSP market growth.

Major Patient Support Programs in Italy

Patient Support Programs	Focus Area	Pharma Sponsor
PSOLife Care	Psoriasis	Novartis
Hemozone	Hemophilia	BIOVIIIx
Clickservice	Growth disorders and GH deficiency	Merck
Contantinus DFU	Diabetic Foot Ulcer	Molteni
Trovarsi	Schizophrenia	Angelini
Lilfully	General wellness	Cheisi
Turbo+	Asthma and COPD	AstraZeneca
Vinci di Salute	Atrial Fibrillation, Acromegaly, Breast cancer, Rheumatoid arthritis and Ulcerative colitis	Philips, Pfizer
Adveva	Multiple sclerosis	Merck
Sandoz One Source	Neutropenia and Hematopoietic Subsyndrome	Sandoz
NoiPerT (r) e	Women’s Health	GSK

Top PSP Operators in Italy

Domedica- an IQVIA business supported clinical centers, patients, and the health ecosystem with innovative solutions and projects: Patient Support Programs (PSP); support and home delivery; emotional and psychological assistance projects; training and education; decentralized and home clinical trials
Sarpharma- Sarpharma specializes in the development of medicinal products, regulatory affairs, market access, pharmacovigilance, and clinical research
Healthcare Network Partners- HNP Italy Srl is the company of the HNP Group - Healthcare Network Partners, which offers assistance services to patients and Clinical Centres with the aim of guaranteeing therapeutic adherence and increasing the value for the patient
Alcura- Alcura offers solutions for companies involved in the development and supply of innovative medicines, to ensure efficient management of clinical trials, market access, and valuable support to patients, so as to improve the outcomes associated with medicines and the achievement of business objectives
Human AssistCare- Human AssistCare's Patient Support Programs (PSP) improve the quality of life of people suffering from rare or chronic diseases and guarantee them the adherence and effectiveness of drug therapy

Healthcare Policies and Regulatory Landscape

From a legal point of view, no specific regulation of PSPs has been developed at the European or national level, however, their existence is recognized in Europe, and to date, they have been regulated from a pharmacovigilance point of view since when a PSP is initiated in relation to specific products, it is essential to comply with pharmacovigilance regulations. PSPs must be designed and implemented by compliance and medical affairs departments in order to avoid any commercial purpose and use.

Italy's association for pharmaceutical companies has amended its Code of Ethics with 4 new articles on PSP and on the promotion of medicines. The Board of Farmindustria, the Italian Pharmaceutical Companies Association, recently approved amendments to its code of conduct that are of interest in connection with information and promotion activities. Key pointers include the provider may send its specialized, qualified, and previously trained personnel to the patient's home or to public or private health facilities, provided that the relationship between the company and the supplier falls within the form of a service contract and The duration of the services offered by the PSP must be previously defined and the corporate function that has the decision-making responsibility of the PSP must not be commercial and must operate under the supervision of the company's compliance function.

1. Executive Summary
1.1 Service Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Healthcare Services Market in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Services
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Italy Patient Support Programs (PSP) Market Segmentation

By Functionality Outlook

Communication
Health Tracking & Insights
Billing & Payments
Administrative
Patient Education
Others

By Therapeutic area outlook

Health & Wellness
Chronic Disease Management
Others

By Application outlook

Population Health Management
Outpatient Health Management
In-patient Health Management
Others

By End-user

Payers
Providers
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.